Jordan Tran, MD
Family Medicine · Winchester, VANPI 1730417338
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $25,440 of the $41,782 with a category attached, or 60.9%. Amgen accounts for 85.4% of it on its own, with 22 other manufacturers making up the rest. Reporting peaked in 2019 at $29,429 and has fallen 94.1% since, to $1,740 in 2025. Among family medicine clinicians in VA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 433 payments — averaging $96.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$36K
- AstraZeneca$1K
- ANI Pharmaceuticals, Inc.$1K
- AbbVie$982
- Lilly USA, LLC$503
- GSK$490
- plus $2K from 17 others
What the payments were for
- Speaking & faculty fees$25,44061%
- Travel & lodging$7,31117%
- Food & beverage$9,02422%
- Education$70%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 125 | $35,694 |
| AstraZeneca(2 entities) | 62 | $1,360 |
| ANI Pharmaceuticals, Inc. | 65 | $1,001 |
| AbbVie | 57 | $982 |
| Lilly USA, LLC | 27 | $503 |
| GSK | 21 | $490 |
| Gilead | 14 | $434 |
| Takeda Pharmaceuticals U.S.A., Inc. | 16 | $318 |
| Astellas Pharma US Inc | 9 | $216 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 9 | $213 |
| Boehringer Ingelheim | 4 | $88 |
| Medtronic | 5 | $84 |
| Vanda Pharmaceuticals Inc. | 3 | $70 |
| Dendreon Pharmaceuticals LLC | 3 | $59 |
| Vyera Pharmaceuticals, LLC | 2 | $52 |
| Novo Nordisk | 3 | $50 |
| Antares Pharma, Inc. | 2 | $39 |
| Romark Laboratories, LC | 1 | $29 |
| Otsuka America Pharmaceutical, Inc. | 1 | $23 |
| OWP Pharmaceuticals, Inc. | 1 | $23 |
| Lundbeck LLC | 1 | $19 |
| Teva Pharmaceuticals USA, Inc. | 1 | $18 |
| Novartis | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- KRYSTEXXA$33,455
- PURIFIED CORTROPHIN GEL$115
How this compares
$41,782 in reported general payments places this provider in the 95th percentile of 2,553 family medicine providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CortrophinCorticotropin | 47 | $6,251,744 |
| KrystexxaPegloticase | 32 | $1,847,344 |
| MounjaroTirzepatide | 25 | $27,497 |
| VraylarCariprazine Hcl | 15 | $24,933 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 36 | $23,017 |
| FarxigaDapagliflozin Propanediol | 28 | $15,664 |
| TrulicityDulaglutide | 13 | $12,935 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 15 | $9,103 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 12 | $5,606 |
| Levothyroxine Sodium | 255 | $1,429 |
| Donepezil Hcl | 62 | $1,331 |
| Testosterone Cypionate | 23 | $1,100 |
| Quetiapine Fumarate | 53 | $828 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 46 | $818 |
| Atorvastatin Calcium | 111 | $576 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AmgenKrystexxa | $35,694 | $1,847,34432 claims |
| Lilly USA, LLCMounjaro, Trulicity | $503 | $40,43138 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $490 | $28,62248 claims |
| AbbVieVraylar | $982 | $24,93315 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $1,360 | $24,76743 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,553 family medicine providers in Virginia.
Other family medicine in Winchester
- Oluwaronke AwosikaFort Gregg Adams$397K
- Monique MatuskowitzNorfolk$110K
- Paul StairsRichmond$105K
- Edwin RobinsonRichmond$83K
- Benjamin PhilpottRocky Mount$64K
- John MolaiyArlington$64K
- Catherine VarneyZion Crossroads$47K
- John ClayColonial Heights$40K
- Thomas RobesonNewport News$34K
- John ScottGlen Allen$28K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.